Renal outcomes of treatment with telmisartan in patients with stage 3-4 chronic kidney disease: A prospective, randomized, controlled trial (JINNAGA).

Mineaki KitamuraHideyuki AraiShinichi AbeYuki OtaKumiko MutaAkira FurusuHiroshi MukaeShigeru KohnoTomoya Nishino

Published in: SAGE open medicine (2020)

Our findings do not demonstrate a direct dose-dependent renoprotective effect of telmisartan. The higher telmisartan dose resulted in a decrease in the amount of urinary protein. Even though high-dose angiotensin II receptor blockers may be preferable for patients with stage 3-4 chronic kidney disease, the clinical importance of the study results may be limited. The study was registered in the UMIN-CTR (https://www.umin.ac.jp/ctr) with the registration number UMIN000040875.

Keyphrases

chronic kidney disease
angiotensin ii
randomized controlled trial
high dose
end stage renal disease
angiotensin converting enzyme
study protocol
skeletal muscle
binding protein
peritoneal dialysis
amino acid
smoking cessation
replacement therapy